Author of

• 12701

  +

  P3.12 - Poster Session 3 - NSCLC Early Stage (ID 206)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12702

    +

    P3.12-001 - Lung Krueppel-like factor KLF2 improve post-operative prognosis of lung adenocarcinoma correlation with chemokine receptor CCR7 and genetical mutations of p53. (ID 30)

    09:30 - 09:30  |  Author(s): H. Tamura
    • Abstract

    Background
    Chemokines and chemokine receptors not only have the powerful ability in cancer metastasis and tumorigenesis, but also act as anti-tumorgenic ability. Lung Krueppel-like factor (LKLF, KLF2) is a member of the family of the Krueppel-like factors (KLFs).　KLF2 was initially described as a lung-specific transcription factor. KLF2 is reported to regulate some malignant cells. We examined and evaluated the effect of KLF2 on lung adenocarcinoma and the relationship of their mRNA expression with CCR7, EGFR and p53 genetical mutations in lung adenocarcinoma.

    Methods
    120 patients of stage I to IV with lung adenocarcinoma were included in this retrospective analysis. The expression of CCR7 and KLF2 mRNA expression in surgically resected lung adenocarcinoma specimens were examined and evaluated the relation to prognosis, the effect of EGFR and p53 genetical mutations. In addition the expression of CCR7 and KLF2 exprssion were analyzed with immunohistochemical analysis and measured their mRNA expression extracted from tissue sections of lung adenocarcinoma specimens by laser capture microdissection.

    Results
    High mRNA expression of KLF2 in lung cancer patients indicated significantly good prognosis than the groups of low expressions (p= 0.0066, HR= 2.008, 95% CI of ratio 1.215 to 3.319). The expression of KLF2 mRNA had relationships with CCR7, CCL21 and CCL19 mRNA expression in lung adenocarcinoma. Moreover the mRNA expression of KLF2 in lung adenocarcinoma specimens was influenced by the mutation of p53 mutation in lung cancer specimens. In addition the expression of KLF2 was confirmed with immunohistochemical analysis and was ditected mRNA expression extracted from tissue sections of lung adenocarcinoma specimens by laser capture microdissection.

    Conclusion
    We propose KLF2 as clinical good prognostic factors and that KLF2 has strong relation with CCR7, the ligands CCL19, CCL21 and p53 genetical mutation in lung adenocarcinoma.